Мария Карибова

Мария Карибова

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SKSofia Kruchinova
Sofia Kruchinova
MGMilana Gendugova
Milana Gendugova
Alim NamitokovAlim Namitokov
Alim Namitokov
MSMaria Sokolskaya
Maria Sokolskaya
IGIrina Gilevich
Irina Gilevich
Vladimir ShvartzVladimir Shvartz
Vladimir Shvartz
Background: Despite the vast evidence of the beneficial effect of vagus nerve stimulation on the course of myocardial infarction confirmed in studies using animal models, the introduction of this method into actual clinical practice remains uncommon. Objective: The objective of our study was to evaluate the effect of transcutaneous vagus nerve stimulation (tVNS) on in-hospital and long-term outcomes for patients with ST-elevation myocardial infarction. Materials and Methods: A blind, randomized, placebo-controlled clinical trial was conducted. The participants were randomly split into two groups. The Active tVNS group was subjected to stimulation of the tragus containing the auricular branch of the vagus nerve. The Sham tVNS group underwent stimulation of the lobule. Stimulation was performed immediately on admission before the start of the percutaneous coronary intervention (PCI). Then, tVNS continued throughout the entire PCI procedure and 30 min after its completion. The primary endpoints were hospital mortality and 12-month mortality. The secondary endpoints were in-hospital and remote non-lethal cardiovascular events. The combined endpoint consisted of major adverse cardiovascular events (MACEs)—recurrent myocardial infarction, stroke/TIA, and overall mortality. Results: A total of 110 patients were randomized into the Active tVNS group (n = 55) and the Sham tVNS group (n = 55). The incidences of hospital mortality, cardiogenic shock, and AV block 3 were statistically less common in the Active tVNS group than in the Sham tVNS group (p = 0.024*, p = 0.044*, and p = 0.013*, respectively). In the long-term period, no statistical differences were found in the studied outcomes obtained following the construction of Kaplan–Meyer survival curves. When comparing groups by total mortality, taking into account hospital mortality, we observed a tendency for the survival curves to diverge (Logrank test, p = 0.066). Statistical significance was revealed by the composite endpoint, taking into account hospital events (Logrank test, p = 0.0016*). Conclusions: tVNS significantly reduced hospital mortality (p = 0.024*), the level of markers of myocardial damage, and the frequency of severe cardiac arrhythmias in patients with acute myocardial infarction. In the long term, the prognostic value of tVNS was revealed by the composite endpoint major adverse cardiovascular events. Further studies with an expanded sample are needed for a more detailed verification of the data obtained to confirm the effectiveness of tVNS and allow an in-depth analysis of the safety and feasibility of its use in routine clinical practice. This clinical trial is registered with ClinicalTrials database under a unique identifier: NCT05992259.

7 April 2023 in Cardiogenetics
Verified
Journal Article
Open access
PDF file
SKSofia Kruchinova
Sofia Kruchinova
Vladimir ShvartzVladimir Shvartz
Vladimir Shvartz
Alim NamitokovAlim Namitokov
Alim Namitokov
MGMilana Gendugova
Milana Gendugova
МКМария Карибова
Мария Карибова
EKElena Kosmacheva
Elena Kosmacheva
(1) Background. One of the causes of myocardial infarction (MI) with nonobstructive coronary arteries (MINOCA) is thrombus formation in situ followed by lysis, resulting in a morphologically normal angiogram but with an underlying prothrombotic state that is potentially predisposed to recurrence. Recent studies have shown that a subset of MINOCA patients may have thrombophilic conditions at screening. Objective: To compare the prothrombotic trend in MINOCA patients with that of subjects with MI and obstructive coronary arteries (MIOCA) by testing for known congenital thrombophilias and markers of coagulation activation. (2) Materials and methods. Screening included congenital thrombophilias (factor V Leiden; assessment of protein C, protein S, and antithrombin III) and eight genes. Of these, four genes represented the folate pathway enzymes: MTHFR 677 C>T (rs1801133), MTHFR 1298 A>C (rs1801131), MTR 2756 A>G (rs1805087), and MTRR 66 A>G (rs1801394). The other four genes represented the blood coagulation system: F13 (163 G>T) rs5985, F1 (−455 G>A) rs1800790, GP IIb–IIIa (1565 T>C) rs5918, and PAI-I (−675 5G>4G) rs1799889. Additionally, we examined the levels of homocysteine and lipoprotein (LP) (a). (3) Results. Our study included 269 patients: 114 MINOCA patients and 155 MIOCA patients with lesions of one coronary artery. The frequencies of polymorphisms in the genes of the blood coagulation system and the folate pathway did not differ between the groups. The following genes were associated with in-hospital mortality in the MINOCA group: MTHFR 1298 A>C rs1801131 (OR 8.5; 95% CI 1.67–43.1) and F1 (−455 G>A) rs1800790 (OR 5.8; 95% CI 1.1–27.8). In the MIOCA group, the following genes were associated with in-hospital mortality: MTHFR 1298 A>C rs1801131 (OR 9.1; 95% CI 2.8–28.9), F1 (−455 G>A) rs1800790 (OR 11.4; 95% CI 3.6–35.9), GP IIb–IIIa (1565 T>C) rs5918 (OR 10.5; 95% CI 3.5–30.8), and PAI-I (−675 5G>4G) rs1799889 (OR 12.9; 95% CI 4.2–39.7). We evaluated long-term outcomes (case fatality rate, recurrent MI, and stroke) over a period of 12 months in both groups. The variables associated with these outcomes were laboratory parameters, such as protein C deficiency, hyperhomocysteinemia, and a content of LP (a) > 30 mg/dL. However, we did not reveal the prognostic value of polymorphisms of the studied genes representing the blood coagulation system and the folate pathway. (4) Conclusion. We established no statistically significant differences between the MINOCA and MIOCA groups in the prevalence of congenital thrombophilias and the prevalence of folate pathway enzyme genes and blood coagulation system genes. The MTHFR 1298 A>C (rs1801131) and F1 (−455 G>A) rs1800790 genes were associated with in-hospital mortality in both groups. More significant prognostic factors in both groups during the one-year period were protein C deficiency, hyperhomocysteinemia, and LP (a) > 30 mg/dL.

19 May 2024 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
SKSofia Kruchinova
Sofia Kruchinova
KSK. V. Skaletsky
K. V. Skaletsky
EDE. K. Donets
E. K. Donets
Alim NamitokovAlim Namitokov
Alim Namitokov
МКМария Карибова
Мария Карибова
EKE. D. Kosmacheva
E. D. Kosmacheva
Introduction. Constrictive pericarditis is a long-term consequence of any pathological process developing in the pericardium due to fibrinous thickening and calcification of its layers, which prevents normal cardiac diastolic filling. One of its forms is transient constrictive pericarditis, which resolves after anti-inflammatory therapy.Brief description. A 19-year-old man with Bruton disease was admitted to the clinic with complaints of severe weakness, shortness of breath at rest, cough, chest pain, hyperthermia to 380 C, decreased blood pressure to 80/60 mm Hg, and abdominal distension. During the initial echocardiography, the results did not raise serious suspicions. However, given the rather specific interventricular septum motion, pericardial constriction was suspected.Discussion. During the additional examination, echocardiography made it possible to verify constrictive pericarditis, which was subsequently confirmed by heart catheterization. Due to significant immunoglobulin level deviations, a decision was made to resume immunoglobulin replacement therapy, followed by a clinical status reassessment.The article presents a clinical description of a patient with constrictive pericarditis, which was a manifestation of Bruton disease. During follow-up, resolution of constriction was noted with resumption of immunoglobulin replacement therapy.

7 May 2025 in Therapy
Verified
Journal Article
Closed access
МКМария Карибова
Мария Карибова
SKSofia Kruchinova
Sofia Kruchinova
GGGendugova M.N. Gendugova
Gendugova M.N. Gendugova
KKKosmacheva E.D. Kosmacheva
Kosmacheva E.D. Kosmacheva

27 February 2025 in Innovative Medicine of Kuban
Verified
Journal Article
Open access
PDF file
МКМария Карибова
Мария Карибова
SKSofia Kruchinova
Sofia Kruchinova
Vladimir ShvartzVladimir Shvartz
Vladimir Shvartz
MGMilana N. Gendugova
Milana N. Gendugova
EKElena D. Kosmacheva
Elena D. Kosmacheva
Background: Heart failure is the outcome of most cardiovascular diseases. Its prevalence continues to increase annually, which emphasizes the importance of developing therapeutic strategies to prevent adverse outcomes. This article reviews current data on the effect of vagus nerve stimulation on the course of chronic heart failure.Objective: To summarize available literature data on the effect of vagus nerve stimulation on the course of chronic heart failure.Materials and methods: We searched PubMed and eLIBRARY for the relevant information over the last 20 years using the following keywords: vagus nerve, heart failure, stimulation, ejection fraction. The search was performed by titles, abstracts, and keywords.Results: This review revealed that vagus nerve stimulation has favorable effects in patients with heart failure and warrants further careful investigation.

27 September 2025 in South Russian Journal of Therapeutic Practice
Verified
Journal Article
Open access
PDF file
МКМария Карибова
Мария Карибова
SKSofia Kruchinova
Sofia Kruchinova
EKE. D. Kosmacheva
E. D. Kosmacheva
   Objective: based on the data from the total register of acute coronary syndrome (ACS) in the Krasnodar Territory, identify the factors associated with reduced LV EF in patients with primary acute myocardial infarction (MI).   Materials and methods: a retrospective study was conducted on 5,655 patients with primary MI included in the total ACS registry in the Krasnodar Territory from 2022 to 2024. The study examined the relationship between LV EF and the clinical, anamnestic, and diagnostic data of the patients. LV EF values were assessed using the Simpson method before discharge from the hospital or earlier in case of hospital-acquired death. Depending on the LV EF, all patients were divided into groups with low (≤ 40 %) LV EF (n = 1125), moderately low (41-49 %) LV EF (n = 1258), and preserved (≥ 50 %) LV EF (n = 3272).   Results: the data of 5,655 patients included in the total ACS registry in the Krasnodar Territory for the period from 2022 to 2024 were analyzed. Factors such as a history of smoking, chronic kidney disease, hypertension, and peripheral atherosclerosis, increased troponin, creatinine > 130 mmol/l, and glucose > 15 mmol/l upon admission according to laboratory blood tests, and ST segment elevation and the formation of a pathological Q wave on an electrocardiogram, as well as acute heart failure (AHF) of class II–IV according to Killip and the presence of early complications of MI were identified as predictors of a decrease in LVEF in patients with primary MI.   Conclusions: presence of smoking, chronic kidney disease, arterial hypertension and peripheral atherosclerosis in the anamnesis, increase in troponin, creatinine > 130 μmol/L and glucose > 15 mmol/L, ST segment elevation, formation of pathological Q-wave, the phenomena of OSN II–IV class according to Killip, and the presence of early complications are associated with a decrease in LV EF in patients with MI.